RevolKa Ltd. announces the closing of a 250 million JPY (US$1.7 million) Series
A extension funding to accelerate Drug-Discovery programs
RevolKa is advancing AI-driven protein engineering platform to create novel therapeutics

Tokyo Japan- Aug 30th, 2024. RevolKa Ltd. (RevolKa), a venture-backed biotech
company providing a cutting-edge AI-driven protein engineering technology platform,
called aiProtein® announced the closing of a 100 million JPY (US$0.7M) financing, andhas completed a total of 250 million JPY (US$1.7M) in the Series A extension funding.
We also announced the launch of a drug discovery program for rare diseases on July
30th, 2024. (https://www.revolka.com/news/english/collab-en/a65) Some of our drugcandidates in this program have achieved positive in vitro proof-of-concept. D3 LLC(Tomoya Nagata, Managing Partner, CEO) co-led the Series A extension round alongwith DEEPCORE Inc. (Katsumasa Niki, President & CEO). The funds will accelerate
RevolKa’s drug discovery and development activities.
Our core technology, aiProtein®: a robust directed protein evolution technology
integrated with AI (artificial intelligence) creates incredibly high performance proteins,
going beyond natural evolution. This technology generated many successful stories incollaboration with partner companies.
About D3 LLC
D3.LLC, founded in 2017, is a healthcare-focused investment, business, and consulting
company. Our mission is to contribute to global healthcare. We go beyond fundingpromising scientific and technological seeds and business ideas (Discovery), working
alongside entrepreneurs to create meaningful products and services and build businessmodels to deliver them to market (Development). We aim for the social implementationof science, technology, and ideas (Deployment). In venture-capital activities, we value
investing in a selected company and providing hands-on support to them in accordancewith global standards in the biotech and healthcare VC.
About DEEPCORE Inc.
DEEPCORE Inc. is a venture capital focused on companies in the fields of AI andadvanced technologies, supporting entrepreneurs who have the vision to change theworld through technology. We invest in pre-seed to early-stage startups in a wide rangeof industries and sectors, including healthcare, manufacturing, and logistics. In addition

to investment activities, we also focus on supporting entrepreneurs. For instance, we areoperating "KERNEL", a community of AI engineers, researchers, and entrepreneurs, and"KERNEL Global Startup Camp", an accelerator program focused on early-stage startups
looking to expand their business overseas.
About aiProtein® Technology
RevolKa’s proprietary technology, aiProtein® is an AI-assisted directed evolution ofproteins. Naturally occurring protein is a linear polymer of amino acids and theirderivatives, which folds into a tertial structure through internal complex atomic interactions
to show biological function. Proteins have evolved into biologically functional molecules
over hundreds of millions of years. The relationship between protein sequence, structure,and function in those highly complex molecules remains poorly understood to rationallydesign a protein sequence for a particular function. Our AI engine is trained withsequence-function relationship data to statistically predict sequences for an evolved
protein function. Furthermore, aiProtein® can evolve more than two functions
simultaneously. This technology is a powerful and cost-effective tool for the creation ofnovel and highly functional proteins for pharmaceutical and industrial uses.
About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in April 2021 by academic
and industry experts in biotechnology and artificial intelligence. Our mission is to create
novel proteins useful for therapeutics and industries by using our own proprietary
technology, aiProtein® to contribute to human well-being. The name "RevolKa" is derived
from the Latin word for evolution, "evolutio” and the Ainu (an indigenous Japanesepeople) word for raise, “reska”. RevolKa’s headquarters are located in Tokyo, Japan withlaboratories located in Sendai. The company’s investors include Tohoku University
Venture Partners Co., Ltd. and SBI Investment Co., Ltd., and newly joined D3 LLC andDEEPCORE Inc.. For more information, visit https://www.revolka.com/en/.

Contact:RevolKa Ltd.
Ayumi Iwase
Email: info@revolka.co.jp